Literature DB >> 12210341

Genetic counseling in hereditary breast/ovarian cancer in Israel: psychosocial impact and retention of genetic information.

Michal DiCastro1, Moshe Frydman, Irit Friedman, Ronit Shiri-Sverdlov, Moshe Z Papa, Boleslaw Goldman, Eitan Friedman.   

Abstract

Genetic counseling for individuals at high risk for developing breast and ovarian cancer (oncogenetic counseling) involves evaluation of cancer risk, psychological assessment, and genetic testing for germline mutations in BRCA1/BRCA2 genes. The long-term psychosocial impact of oncogenetic counseling on consultees and the retention of oncogenetic information are uncertain. We retrospectively interviewed 155 women who underwent oncogenetic counseling in a single medical center in Israel in 1996 (N = 50) and 1998 (N = 105). There were 29 (18.7%) BRCA1/BRCA2 mutation carriers and 126 non-carriers; 58 (37.4%) had a past or present history of cancer, and 97 (62.6%) were first-degree relatives within breast/ovarian cancer families. A questionnaire evaluating self-reported distress and anxiety symptoms before and after counseling, as well as the retention of relevant information (e.g., individual and offspring cancer risk, early detection schemes), one and three years after the initial consultation was administered. Overall, oncogenetic counseling had a minimal effect on anxiety-related symptoms. Mutation carriers reported anxiety-associated symptoms, such as sleeplessness and "bad mood", more frequently than non-carriers following oncogenetic counseling. As expected, 61.8% of carriers and only 30% of non-carriers accurately remembered the personal and offspring cancer risk and preventive and early detection schemes. We conclude that although there seemed to be slight worsening of anxiety-related symptoms following oncogenetic counseling in BRCA1/BRCA2 mutation carriers, these symptoms were minimal and did not affect everyday life activities. In addition, there is an ongoing need to emphasize oncogenetic information to high-risk individuals. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12210341     DOI: 10.1002/ajmg.10550

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  8 in total

1.  Supervision of psychosocial skills in genetic counseling.

Authors:  L DiAnne Borders; Sonja Eubanks; Nancy Callanan
Journal:  J Genet Couns       Date:  2006-08       Impact factor: 2.537

2.  Psychological distress in women at risk of hereditary breast/ovarian or HNPCC cancers in the absence of demonstrated mutations.

Authors:  Amy Østertun Geirdal; Jon G Reichelt; Alv A Dahl; Ketil Heimdal; Lovise Maehle; Astrid Stormorken; Pål Møller
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

3.  Evaluation of psychosocial effects of pre-symptomatic testing for breast/ovarian and colon cancer pre-disposing genes: a 12-month follow-up.

Authors:  Brita Arver; Aina Haegermark; Ulla Platten; Annika Lindblom; Yvonne Brandberg
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

4.  A pilot randomized clinical trial evaluating the impact of genetic counseling for serious mental illnesses.

Authors:  Catriona Hippman; Andrea Ringrose; Angela Inglis; Joanna Cheek; Arianne Y K Albert; Ronald Remick; William G Honer; Jehannine C Austin
Journal:  J Clin Psychiatry       Date:  2016-02       Impact factor: 4.384

5.  Distress and family functioning in oncogenetic counselling for hereditary and familial breast and/or ovarian cancers.

Authors:  C Condello; R Gesuita; M Pensabene; I Spagnoletti; I Capuano; C Baldi; F Carle; A Contegiacomo
Journal:  J Genet Couns       Date:  2007-08-15       Impact factor: 2.537

6.  Family communication in a population at risk for hypertrophic cardiomyopathy.

Authors:  Brittany Batte; Jane P Sheldon; Patricia Arscott; Darcy J Huismann; Lisa Salberg; Sharlene M Day; Beverly M Yashar
Journal:  J Genet Couns       Date:  2014-10-12       Impact factor: 2.537

7.  Permanence of the information given during oncogenetic counseling to persons at familial risk of breast/ovarian and/or colon cancer.

Authors:  Fabrice Kwiatkowski; Pascal Dessenne; Claire Laquet; Marie-Françoise Petit; Yves-Jean Bignon
Journal:  Eur J Hum Genet       Date:  2011-09-21       Impact factor: 4.246

8.  BRACAVENIR: an observational study of expectations and coping in young women with high hereditary risk of breast and ovarian cancer.

Authors:  Fabrice Kwiatkowski; Mathilde Gay-Bellile; Pascal Dessenne; Claire Laquet; Véronique Boussion; Marie Béguinot; Marie-Françoise Petit; Anne-Sophie Grémeau; Céline Verlet; Charlotte Chaptal; Marilyn Broult; Sylvie Jouvency; Martine Duclos; Yves-Jean Bignon
Journal:  Hered Cancer Clin Pract       Date:  2019-02-27       Impact factor: 2.857

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.